Aeglea a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. Aeglea has two pipeline programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. Source
No articles found.
Clean Bite is a toothbrush for people who want to brush their teeth whenever situa...
Clean Bite is a toothbrush for people who want ...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
PAVmed Inc. is a highly differentiated, multiproduct medical device company employ...
PAVmed Inc. is a highly differentiated, multipr...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
Join the National Investor Network and get the latest information with your interests in mind.